Fidia S.p.A. (BIT:FDA)
Italy · Delayed Price · Currency is EUR | Market Cap | 2.16M |
| Revenue (ttm) | 17.53M |
| Net Income (ttm) | -9.30M |
| Shares Out | 7.47M |
| EPS (ttm) | -32.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 36,431 |
| Average Volume | 454,611 |
| Open | 0.2820 |
| Previous Close | 0.2888 |
| Day's Range | 0.2810 - 0.2940 |
| 52-Week Range | 0.2000 - 26.4000 |
| Beta | 0.05 |
| RSI | 33.22 |
| Earnings Date | Sep 11, 2025 |
About United States Steel
Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems. Its accessories comprise HMS, a device for measuring and compensating geometric error on continuous or indexed bi-rotary heads and roto-tilting tables; TMSC, a device to measure length and diameter of the tool, as well as to check the shape; K5 tracer, a solution to perform continuous scanning of 3D surfaces; pushbutton panels; XPower digital drives for axis and spindle movement; and... [Read more]
Financial Performance
In 2024, Fidia's revenue was 17.53 million, a decrease of -38.98% compared to the previous year's 28.74 million. Losses were -9.30 million, 611.4% more than in 2023.
Financial StatementsNews
More than 20 GOP attorneys general call on RFK Jr, FDA to reinstate safeguards for abortion drugs
More than 20 Republican attorneys general are demanding that the Trump administration reinstate safety protocols for the abortion drug mifepristone.
FDA Grants 510(k) Clearance for Sonic Incytes’ Velacur ONE™, AI-Guided Point of Care Ultrasound for the Management of Chronic Liver Diseases
VANCOUVER, British Columbia — Sonic Incytes Medical Corp, proudly announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Velacur ONE™, its point-of-care ultrasound...
FDA may pull authorization of Pfizers Covid vaccine for children under 5
The potential move to rescind authorization of Pfizer's vaccine could leave some kids in the U.S. with no available shots against Covid.
Why Is Liquidia Stock Trading Higher On Tuesday?
Liquidia Corporation (NASDAQ: LQDA) reported on Tuesday a second-quarter loss of 49 cents, missing the consensus of a loss of 43 cents . See the LGDA stock price story here. Sales reached $8.84 milli...
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease
The FDA approves Insmed's Brinsupri for NCFB, ... Full story available on Benzinga.com
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency
A group of former U.S. Centers for Disease Control and Prevention (CDC) employees are blaming HHS Secretary Robert F. Kennedy Jr. for vilifying the agency’s workforce through “his continuous lies abou...
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval
Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a devastating lung condition.
Insmed wins FDA approval for lung disorder therapy Brinsupri
Insmed (INSM) stock rises as the FDA greenlights its lung disorder drug Brinsupri for patients with on-cystic fibrosis bronchiectasis. Read more here.
FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10 mg and 25 mg Doses App...
Altimmune Q2 FY2025 Earnings Call Transcript
Altimmune, Inc. (NASDAQ: ALT) reported its second-quarter financial results before Tuesday’s opening bell. Below are the transcripts from the Q2 earnings call. This transcript is brought to you by Be...
Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder
Novartis AG (NYSE: NVS) released topline results on Tuesday from the VAYHIT2 Phase 3 trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously trea...
Ocular gets FDA agreement for registrational trial of Axpaxl
Pfizer/BioNTech may not win FDA renewal for pediatric COVID shot: report
CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in early 2026 Productive initial meeting with the FDA on Auxora in acute pan...
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply
View Preview Pfizer Inc.'s (NYSE: PFE) COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and pro...
Amphastar gets FDA nod for generic iron sucrose injection
IO Biotech's Combo Therapy For Skin Cancer Falls Just Short, Eyes FDA Talks Later This Year
IO Biotech's Phase 3 trial showed ... Full story available on Benzinga.com
Viatris wins FDA nod for generic iron sucrose injection targeting Daiichi’s Venofer
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
In a stunning reversal, Dr. Vinay Prasad is returning to his role as director of the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER), just days after his ...
GSK bid to expand Blujepa label for gonorrhea granted FDA priority review
FDA's vaccine chief returning to job a week after leaving: Report
CNBC's Joe Kernen reports on the latest news.